2013
DOI: 10.1016/j.lungcan.2012.09.009
|View full text |Cite
|
Sign up to set email alerts
|

Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: Case report and literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
20
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(29 citation statements)
references
References 17 publications
1
20
0
Order By: Relevance
“…There are few published cases of cutaneous lymphangitis carcinomatosa and, to our knowledge, this is the first case of cutaneous lymphangitis carcinomatosa associated with paraneoplastic DM 1113…”
Section: Discussionmentioning
confidence: 81%
“…There are few published cases of cutaneous lymphangitis carcinomatosa and, to our knowledge, this is the first case of cutaneous lymphangitis carcinomatosa associated with paraneoplastic DM 1113…”
Section: Discussionmentioning
confidence: 81%
“…Although little data exist on the prevalence of other subtypes, smaller case reports of cutaneous metastases from lung cancer include descriptions of telangiectatic, erysipelas-like, and zosteriform patterns. Carcinoma erysipeloides secondary to lung cancer is rarely described, with our search finding only 7 prior case reports 7, 8, 9. In women, skin metastases are overwhelmingly related to breast cancer followed by ovarian and oral cavity cancers 4 .…”
Section: Discussionmentioning
confidence: 95%
“… 2 7 The most common histological feature observed in patients with lung cancer who develop CLC is adenocarcinoma, as in the present case. 8 Cutaneous metastasis in lung cancer tends to occur in order in the anterior chest wall, back and abdomen. 7 9–11 Cutaneous metastases are considered a late event in the evolution of the majority of malignancies.…”
Section: Discussionmentioning
confidence: 99%
“… 3 7 12 The only known treatment for CLC is systemic chemotherapy, but early diagnosis can lead to earlier anticancer treatment. 8 Osimertinib may improve the prognosis of the patients harbouring the EGFR T790M mutation; however, osimertinib was not available for treatment at the time of this diagnosis. 13–15 Supportive care for lymphoedema due to CLC, as follows, can improve patients’ quality of life and may even influence the progression of the disease: manual lymph drainage, compression therapy with bandages or special stockings, dermatological skin care and psychological treatment.…”
Section: Discussionmentioning
confidence: 99%